RNA Editing Enzyme ADAR1 Emerges as Key Switch That Turns Cold Bladder Tumors Hot
Researchers found that inhibiting the RNA editing enzyme ADAR1 reprograms the immunosuppressive tumor microenvironment of bladder cancer and sensitizes it ...
Researchers found that inhibiting the RNA editing enzyme ADAR1 reprograms the immunosuppressive tumor microenvironment of bladder cancer and sensitizes it ...
A new Molecular Cancer review proposes immune-pressure redistribution as a unifying framework explaining why patients resist PD-1/PD-L1 blockade and how ...
The Phase 3 EVOKE-03/KEYNOTE-D46 trial found that sacituzumab govitecan plus pembrolizumab did not significantly improve progression-free or overall survival compared ...
First clinical data from the Phase 1b/2 BNT324-01 trial show that the investigational combination of pumitamig and elfetabart drozuntecan achieved ...
A real-world study of 55 patients with advanced ROS1-rearranged non-small cell lung cancer shows that fusion subtype, PD-L1 expression and ...
A prospective imaging study shows that radium-223 significantly reduces PD-L1 expression and depletes immune cells in prostate cancer bone metastases, ...
Researchers are using PD-L1-targeted PET/CT imaging to directly visualise whether the immunotherapy drug atezolizumab saturates its target in tumours, offering ...
A new review in the Journal of Translational Medicine details how the RNA methyltransferase METTL3 drives tumor immune escape through ...
A full-thickness biopsy study of 40 dogs reveals that PD-L1 expression, rather than conventional histological features, is the strongest predictor ...
© 2026 Scienmag - Science Magazine
© 2026 Scienmag - Science Magazine